Cardiol Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. The analyst looks for CardiolRx to achieve blockbuster drug status. CardiolRx is a Phase 2 stage, pharmaceutical-grade, proprietary cannabidiol oral solution in development as a treatment for recurrent pericarditis and acute myocarditis, the analyst tells investors in a research note. The firm says recurrent pericarditis represents a significant unmet medical need.